Evidence map›Paper›PMID 25155603›Full record

ArticleAntimicrobial agents and chemotherapy2014

The 6-Aminoquinolone WC5 inhibits different functions of the immediate-early 2 (IE2) protein of human cytomegalovirus that are essential for viral replication.

Beatrice Mercorelli, Anna Luganini, Giulia Muratore, Serena Massari, Maria Elena Terlizzi, Oriana Tabarrini, Giorgio Gribaudo, Giorgio Palù, Arianna Loregian

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Beatrice MercorelliDepartment of Molecular Medicine, University of Padua, Padua, Italy.
Anna LuganiniDepartment of Life Sciences and Systems Biology, University of Turin, Turin, Italy.
Giulia MuratoreDepartment of Molecular Medicine, University of Padua, Padua, Italy.
Serena MassariDepartment of Chemistry and Technology of Drugs, University of Perugia, Perugia, Italy.
Maria Elena TerlizziDepartment of Life Sciences and Systems Biology, University of Turin, Turin, Italy.
Oriana TabarriniDepartment of Chemistry and Technology of Drugs, University of Perugia, Perugia, Italy.
Giorgio GribaudoDepartment of Life Sciences and Systems Biology, University of Turin, Turin, Italy giorgio.gribaudo@unito.it giorgio.palu@unipd.it arianna.loregian@unipd.it.
Giorgio PalùDepartment of Molecular Medicine, University of Padua, Padua, Italy giorgio.gribaudo@unito.it giorgio.palu@unipd.it arianna.loregian@unipd.it.
Arianna LoregianDepartment of Molecular Medicine, University of Padua, Padua, Italy giorgio.gribaudo@unito.it giorgio.palu@unipd.it arianna.loregian@unipd.it.
University of Padua · ITUniversity of Turin · ITUniversity of Perugia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human cytomegalovirus (HCMV) immediate-early 2 (IE2) protein is a multifunctional factor essential for viral replication. IE2 modulates both viral and host gene expression, deregulates cell cycle progression, acts as an immunomodulator, and antagonizes cellular antiviral responses. Based on these facts, IE2 has been proposed as an important target for the development of innovative antiviral approaches. We previously identified the 6-aminoquinolone WC5 as a promising inhibitor of HCMV replication, and here, we report the dissection of its mechanism of action against the viral IE2 protein. Using glutathione S-transferase (GST) pulldown assays, mutagenesis, cell-based assays, and electrophoretic mobility shift assays, we demonstrated that WC5 does not interfere with IE2 dimerization, its interaction with TATA-binding protein (TBP), and the expression of a set of cellular genes that are stimulated by IE2. On the contrary, WC5 targets the regulatory activity exerted by IE2 on different responsive viral promoters. Indeed, WC5 blocked the IE2-dependent negative regulation of the major immediate-early promoter by preventing IE2 binding to the crs element. Moreover, WC5 reduced the IE2-dependent transactivation of a series of indicator constructs driven by different portions of the early UL54 gene promoter, and it also inhibited the transactivation of the murine CMV early E1 promoter by the IE3 protein, the murine cytomegalovirus (MCMV) IE2 homolog. In conclusion, our results indicate that the overall anti-HCMV activity of WC5 depends on its ability to specifically interfere with the IE2-dependent regulation of viral promoters. Importantly, our results suggest that this mechanism is conserved in murine CMV, thus paving the way for further preclinical evaluation in an animal model.

Indexed as

AminoquinolinesAntigens, ViralAntiviral AgentsCell Cycle CheckpointsCell LineCyclin ECytomegalovirusDNA-Directed DNA PolymeraseElectrophoretic Mobility Shift AssayGene Expression RegulationHEK293 CellsHumansImmediate-Early ProteinsPromoter Regions, GeneticProtein BindingProtein MultimerizationAminoquinolinesAntigens, ViralAntiviral AgentsCyclin EDNA-Directed DNA PolymeraseImmediate-Early Proteinsimmediate-early proteins, cytomegalovirusQuinolonesUL54 protein, Human herpesvirus 5Viral ProteinsWC5 compound

Identifiers

PMID25155603
PMCPMC4249379
OpenAlexW2163551436

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.